What is Emme?
Emme operates at the forefront of the women's health technology market, specifically targeting the contraceptive experience. Founded in 2017 by Amanda French and Janene Fuerch, MD, the company addresses the high rate of missed birth control pills through its flagship Emme Smart Case and integrated mobile application. The platform utilizes patent-pending, multi-sensor technology to provide real-time tracking, persistent reminders, and personalized contraceptive guidance. By digitizing the pill-taking process, Emme provides a comprehensive health dashboard that tracks cycles, moods, and side effects, effectively bridging the gap between traditional pharmaceutical use and 21st-century digital health expectations.
How much funding has Emme raised?
Emme has raised a total of $2.5M across 1 funding round:
Angel/Seed
$2.5M
Angel/Seed (2020): $2.5M, investors not publicly disclosed
Key Investors in Emme
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Emme?
With this major enterprise-level funding, Emme is poised to accelerate its product development roadmap and broaden its market reach. The strategic focus will likely center on deepening user engagement through enhanced app features and potentially expanding its hardware ecosystem to cover a wider range of reproductive health needs. As the femtech industry continues to mature, Emme's ability to leverage its unique data set will be critical in establishing long-term partnerships with healthcare providers and insurers. The company is well-positioned to transition from a niche hardware provider to a comprehensive digital health platform, setting a new standard for how women manage their reproductive health in an increasingly connected world.
See full Emme company page
